Page last updated: 2024-10-26

diphenyleneiodonium and Scleroderma, Systemic

diphenyleneiodonium has been researched along with Scleroderma, Systemic in 1 studies

diphenyleneiodonium: structure in first source; NADPH oxidase inhibitor
dibenziodolium : An organic cation that is fluorene in which the methylene group is replaced by a positively charged iodine.

Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dosoki, H1
Stegemann, A1
Taha, M1
Schnittler, H1
Luger, TA1
Schröder, K1
Distler, JH1
Kerkhoff, C1
Böhm, M1

Other Studies

1 other study available for diphenyleneiodonium and Scleroderma, Systemic

ArticleYear
Targeting of NADPH oxidase in vitro and in vivo suppresses fibroblast activation and experimental skin fibrosis.
    Experimental dermatology, 2017, Volume: 26, Issue:1

    Topics: Actins; Adult; Animals; Cells, Cultured; Collagen Type I; Collagen Type I, alpha 1 Chain; Computer S

2017